(CercleFinance.com) – Carmat announces the completion of its capital increase with elimination of shareholders’ preferential subscription rights through a public offer, for a total gross amount of 16.5 million euros, including the partial exercise of the over-allotment option for 1.5 million.
The medical technology company plans to use these funds to strengthen its equity and finance its working capital in the short term, and in particular to continue the development of its production and sales, as well as its EFICAS clinical trial in France.
After the offer, Carmat’s financing requirement over a 12-month period is approximately 50 million euros (with a financial horizon of the end of February 2024), which can be reduced to 35 million (with a financial horizon of mid-2024). May 2024) in the event of a final agreement with the EIB.